The US Food and drug administration has approved the first oral drug that can be used to treat COVID-19 infection 22 days for the treatment of adults with newly diagnosed mild to moderate diseases and adults aged 12 and over. Pfizer's oral drug, paxlovid, consists of two antiviral drugs, the FDA said in a statement. Patients should take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the emergence of the symptoms of the new crown. The continuous use time should not exceed 5 days. The statement said that after evaluating all available scientific basis, the FDA believes that paxlovid may be effective in the treatment of patients with mild to moderate symptoms of new crown, and its known and potential benefits outweigh its known and potential risks. Common side effects of the drug may include impaired taste, diarrhea, high blood pressure and muscle soreness. Kauwa Johnny, director of the center for drug evaluation and research of the US drug administration, said that with the emergence of new variant strains, COVID-19's prevention and control had entered a critical stage. The urgent authorization to use the oral medicine provided a new tool for fighting COVID-19. (outlook new era)